259 related articles for article (PubMed ID: 9303058)
1. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
[TBL] [Abstract][Full Text] [Related]
2. The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
Everse LA; Bernsen MR; Dullens HF; Den Otter W
J Exp Ther Oncol; 1996 Jul; 1(4):231-6. PubMed ID: 9414409
[TBL] [Abstract][Full Text] [Related]
3. Effective immunotherapy with local low doses of interleukin-2.
Den Otter W; Maas RA; Koten JW; Dullens HF; Bernsen M; Klein WR; Rutten VP; Steerenberg PA; Balemans L; Ruitenberg EJ
In Vivo; 1991; 5(6):561-5. PubMed ID: 1810439
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
5. Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study.
Everse LA; Renes IB; Jürgenliemk-Schulz IM; Rutgers DH; Bernsen MR; Dullens HF; Den Otter W; Battermann JJ
Int J Cancer; 1997 Sep; 72(6):1003-7. PubMed ID: 9378533
[TBL] [Abstract][Full Text] [Related]
6. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
7. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
9. Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy.
Ohguri T; Imada H; Nomoto S; Yahara K; Hisaoka M; Hashimoto H; Tokura Y; Nakamura K; Shioyama Y; Honda H; Terashima H; Moroi Y; Furue M; Korogi Y
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1446-53. PubMed ID: 15817349
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.
Maas RA; Dullens HF; De Jong WH; Den Otter W
Cancer Res; 1989 Dec; 49(24 Pt 1):7037-40. PubMed ID: 2582444
[TBL] [Abstract][Full Text] [Related]
11. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model.
Chakrabarty A; Hillman GG; Maughan RL; Ali E; Pontes JE; Haas GP
In Vivo; 1994; 8(1):25-31. PubMed ID: 8054507
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
Grégoire V; Hunter N; Milas L; Brock WA; Plunkett W; Hittelman WN
Cancer Res; 1994 Jan; 54(2):468-74. PubMed ID: 8275483
[TBL] [Abstract][Full Text] [Related]
18. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
20. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]